ImmunityBio stock rose 19.8% after FDA meeting on ANKTIVA bladder cancer treatment. Company to submit additional data within ...

ImmunityBio Inc. (NASDAQ:IBRX) shares climbed nearly 20% in premarket trading on Tuesday after the company said it held positive discussions with the U.S. Food and Drug Administration regarding its ...

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its ...

Dr. Soon-Shiong is hopeful the Saudi Arabian FDA's approval of his cancer therapy drug, Anktiva, will lead to widespread ...

Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.

ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...

Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

Investing.com -- ImmunityBio Inc (NASDAQ:IBRX) stock surged 19.8% in premarket trading Tuesday after the company reported ...

Detailed price information for Biovaxys Technology Corp (BVAXF) from The Globe and Mail including charting and trades.

Using multiparametric MRI (mpMRI) before surgery reduced time to correct treatment by 45 days for patients with muscle invasive bladder cancer. The imaging procedure was successful for over 92% of ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...